Trump's Budget will Gut Cancer Research

Article

Trump proposed budget cuts to National Institutes of Health, National Cancer Institute and Medicaid

We all know that there is a cure for cancer, and it’s called money. Over the past two decades the funds allocated for cancer research by the government have been consistently increased but not nearly enough for researchers to spend the time and hours in the lab to beat this stealthy disease — that now kills thousands of Americans a day.

That is the Titanic going down daily. Two days of cancer loss are the equivalent to the number of people we lost when the twin towers fell. Cancer kills men, women and children without discriminating.

And now Trump wants to severely cut funding to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including 20 percent proposed funding cut for the national Institutes of Health (NIH), more cuts proposed cut for the National Cancer Institute (NCI), and reducing Medicaid funding by more than $800 billion.

“Such extreme reductions to programs that are critical to research will fundamentally damage our nation’s progress in treating patients and will irreversibly harm our nation’s already fragile biomedical research infrastructure,” says Daniel F. Hayes, president of the American Society of Clinical Oncology (ASCO) in a statement released this week. ASCO, the largest organization of its kind in the world, represents some 40,000 oncology professionals.

The cuts come at a time when the outlook for cancer patients has improved to the point that there are 15 million cancer survivors in the U.S. compared to seven million in 1991 and three million in 1971. Research has allowed treatments to become targeted to a patient’s cancer type, genetics, age and health status.

Government funding provides the basic research that are the keys to many of the findings about cancer’s genetics and biology.

Federal research funding also provides economic strength and scientific leadership, supporting more than 400,000 jobs and contributing $60 billion in economic activity annually, according to facts included in an ASCO release.

“Biomedical research is one of our nation’s best investments, and we urge Congress to build on the momentum they have created and provide robust increases for NIH in FY 2018,” Hayes says. “Our biomedical research infrastructure is vital to sustaining the health and safety of our citizens. If allowed to crumble, it will take decades to rebuild.”

What can be done about this? The American people need to raise an outcry that their lives are more valuable than a wall.

Write your elected officials and let them know how you feel. That not only should Trump not cut funding, he needs to increase it.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Related Content